H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents

在之前的U 54资助期间，我们专注于开发一类新型的snall分子口服非激素 抗精子生成避孕药。其中，H2-gamendazole（H2-GMZ）现已被鉴定 最有希望的是，100%口服生物利用度，100%不孕，随后100%恢复生育能力， 大鼠，交配行为没有损失。在非人类灵长类动物中进行的初步概念验证研究完全表明， 精子细胞计数和精液精子计数可逆性下降，无不良副作用。H2-GMZ 被Sertoli细胞迅速吸收，似乎通过与精子细胞结合， 与顶端外质特化相关的eEF 1A-F-肌动蛋白束的破坏。一个替代 一种化合物，那西克拉新（NAR），也被确定对非肿瘤细胞具有类似的破坏作用。 支持细胞中典型的eEF 1A-肌动蛋白捆绑功能。为了实现移动H2的总体目标， GMZ对FDA IND状态和临床试验，非人灵长类动物的关键疗效数据，详细说明所有 H2-GMZ作用机制的步骤，以及谨慎发现替代化学先导物， needed.因此，该项目的总体假设是H2-GMZ和其他小分子， 可逆地破坏支持细胞中eEFIA-肌动蛋白捆绑可以被开发为临床上有用的可逆的 抗精子生成避孕药。为实现这些目标，提出了三个具体目标： 目的1：确定口服低剂量H2-GMZ作为一种可逆的抗肿瘤药物的概念验证疗效和药代动力学。 在非人类灵长类动物中的抗精子生成避孕药。 目的2：确定H2-GIZ/IZ和新的小分子引起的eEF 1A放线菌束的变化的机制 以及翻译后修饰对精子细胞过早丢失的影响。 目的3：鉴定和优化模拟H2-GMZ-eEF 1A作用的其他新的选择性小分子，作为抗肿瘤药物。 生精避孕药。 这些努力的成功将提供最终将H2-GMZ转移到 临床前毒理学和注册为FDA IND，用于启动人体临床试验。

In the previous U54 funding period, we focused on developing a class of novel snnall molecule oral nonhormonal anti-spermatogenic contraceptive agents. Of these, H2-gamendazole (H2-GMZ) is now identified as most promising, with 100% oral bioavailability, and 100% infertility followed by 100% recovery of fertility in rats, with no loss in mating behavior. Pilot proof-of-concept studies in non-human primates showed completely reversible declines in spermatid count and semen sperm count with no adverse side effects. H2-GMZ is rapidly absorbed by Sertoli cells and appears to cause premature release of spermatids via binding to and disruption of the eEF1A-F-actin-bundles associated with the apical ectoplasmic specializations. An alternative compound, narciclasine (NAR), has also been identified with similar disruptive effects on the non canonical eEF1A-actin bundling function in Sertoli cells. In order to achieve the overall goal of moving H2 GMZ towards FDA IND status and clinical trials, critical efficacy data in non-human primates, elaborate all of the steps in the mechanism of action of H2-GMZ, and prudent discovery of alternative chemical leads are needed. Thus, the overall hypothesis for this project is that H2-GMZ and other small molecules that reversibly disrupt eEFIA-actin bundling in Sertoli cells can be developed as clinically useful reversible anti-spermatogenic contraceptive agents. Three specific aims are proposed to achieve these goals: Aim 1: Determine proof-of concept efficacy and pharmacokinetics of oral low-dose H2-GMZ as a reversible anti-spermatogenic contraceptive agent in non-human primates. Aim 2: Determine the mechanism of H2-GI\/IZ and novel small molecule-elicited changes in eEF1A actinbundling and post-translational modification on premature loss of spermatids. Aim 3: Identify and optimize other novel selective small molecules that mimic H2-GMZ-eEF1A actions as anti- spermatogenic contraceptive agents. Success in these endeavors will provide essential data needed to enable ultimately moving H2-GMZ into pre-clinical toxicology and registration as an FDA IND for the start of clinical trials in humans.